Assess ustekinumab efficacy ( week 24/week 52 ) and safety ( week 16/week 24/week 60 ) in patients with active psoriatic arthritis ( PsA ) despite treatment with conventional and/or biological anti-tumour necrosis factor ( TNF ) agents .